SEC Form EFFECT filed by Rein Therapeutics Inc.
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 5, 2025 4:30 P.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 5, 2025 4:30 P.M. |
Form: | S-1 | ||||||
|
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/22/2025 | $10.00 | Buy | H.C. Wainwright |
1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press. The paper, titled "LTI-03 peptide demonstrates anti-fibrotic activity in ex vivo lung slices from IPF patients," reports how LTI-03 was tested directly on lung tissue donated by patients with idiopathic pulmonary fibrosis (IPF) who underwent lung transplant. In this model, LT
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the Company to initiate its Phase 2 "RENEW" clinical trial of LTI-03, the Company's lead drug candidate for idiopathic pulmonary fibrosis (IPF). IPF is a serious, progressive lung disease that affects hundreds of thousands of people worldwide. It scars the lungs, leaving patients short of breath and with limited treatment options. Median
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced that Chief Scientific Officer, Cory Hogaboam, and Chief Executive Officer, Brian Windsor, will each present at the IPF Summit 2025, taking place August 19-21, 2025, in Boston, MA. Dr. Hogaboam will present at 8:00 am on Tuesday in a workshop titled, "Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation." He will di
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
8-K - Rein Therapeutics, Inc. (0001420565) (Filer)
EFFECT - Rein Therapeutics, Inc. (0001420565) (Filer)
H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00